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Critical Congenital Heart Disease:  
New Screening Guidelines 
 
SCOPE OF THE PROBLEM 
Congenital heart disease occurs in 9 of every 1,000 live births.1 About 25% of these babies will have 
critical congenital heart disease (CCHD) where by surgery or transcatheter intervention is required in 
the first year of life.2 In the United States, almost all types of congenital heart defects can be surgically 
repaired or palliated, and survival rates continue to improve. Early recognition and timely intervention 
can improve outcomes for these patients. The physical findings consistent with congenital heart 
disease, such as heart murmurs, tachypnea, or overt cyanosis may not be evident before the newborn is 
discharged from the hospital. Pulse-oximetry monitoring, a noninvasive method to determine oxygen 
saturation and identify hypoxemia has been proposed as one strategy for early detection of CCHD. 
 
BACKGROUND 
In August 2009, a writing group appointed by the American Academy of Pediatrics (AAP) and the 
American Heart Association (AHA) reviewed the available evidence and published a statement 
regarding the use of pulse oximetry to detect critical congenital heart disease in newborns.3 They also 
examined the burden of missed and/or delayed diagnosis of CCHD. The group concluded that delayed 
diagnosis was associated with increased morbidity and mortality. They could not determine how many 
deaths might be prevented with pulse-oximetry screening, but the group concluded that it is a viable 
strategy to improve early detection of CCHD. They also called for further studies in larger populations 
across a broad range of newborn delivery systems.  Pulse oximetry cannot detect all cases of CCHD, 
and parents and caretakers should be advised that a negative test result does not exclude the possibility 
of heart disease. 
 
In September 2010, the US Health and Human Services (HHS) Secretary’s Advisory Committee on 
Heritable Disorders in Newborns and Children (SACHDNC) recommended that critical congenital 
cyanotic heart disease be added to the uniform newborn screening panel. Their goal was to identify 
early in life those newborns with structural heart defects usually associated with hypoxia that could 
result in significant morbidity or death with closing of the ductus arteriosus or other physiologic 
changes in the newborn period. An expert technical panel recommended 7 specific lesions as the 
primary targets for screening: hypoplastic left heart syndrome (HLHS); pulmonary atresia; tetralogy of 
Fallot; total anomalous pulmonary venous return; transposition of the great arteries; tricuspid atresia; 
and truncus arteriosus.  This recommendation from the SACHDNC was based on the 2009 statement 
from the AAP and AHA and two recent prospective studies of pulse-oximetry screening on healthy 
newborns in Sweden4 and Germany.5 
 
WORK GROUP CONVENED 
In January 2011, a work group chosen by the SACHDNC, the AAP, the AHA and the American 
College of Cardiology Foundation (ACCF) was convened to outline screening implementation 
strategies. Members included primary care providers; pediatric cardiologists; neonatologists; nurses; 
representatives from the AAP, the ACCF, the AHA, the American College of Medical Genetics; the 
March of Dimes; the Association of Maternal and Child Health Programs; the Association of Public 
Health Laboratories; the SACHDNC; parent screening advocates; state public health officials; and 
representatives from the CDC, the FDA, the HRSA, and the NIH. The group also included people from 
hospitals in Arkansas, California, Minnesota, New York, Washington, and Washington DC who have 
implemented pulse-oximetry screening for CCHD in their nurseries. The 2-day work group meeting 
was open to the public. The meeting focused on recommendations for pulse-oximetry screening for 
CCHD, developing service infrastructure for follow-up and addressing knowledge gaps. The work 
group recognized that many newborns with the targeted congenital heart defects do not develop 
“clinically appreciable cyanosis” until after discharge from the hospital. And, with some lesions such 
as HLHS newborns have significant cardiovascular compromise without apparent cyanosis. Therefore, 
they recommended that the SACHDNC rename the target conditions “critical congenital heart disease” 
(CCHD). The word cyanotic was omitted. The work group recommendations for a standardized 
approach to screening and diagnostic follow-up were published in Pediatrics in November 2011, 
“Strategies for Implementing Screening for Critical Congenital Heart Disease.” 6 
 
RECOMMENDATIONS FOR PULSE OXIMETRY SCREENING AND FOLLOW-UP 
Screening Population and Targets 
• All newborns admitted to the well-infant nursery should be screened using the work-group 
protocol (Figure 1). 
• Newborns in intermediate care nurseries or other units in which discharge is common in the 
first week of life should be screened using the work-group protocol (Figure 1). 
• Out-of-hospital births are not currently included in the screening protocol. 
• The primary goal for screening is identification of the 7 specific lesions associated with CCHD 
per the SACHDNC recommendation. 
• Secondary targets, other hypoxic cardiac- or non-cardiac associated conditions (eg, persistent 
pulmonary hypertension) may be detected. 
 
Screening Technology and Personnel 
• Screening should be performed with motion-tolerant oximeters7 that report functional oxygen 
saturation and have been cleared by the FDA for use in newborns. 
• Pulse oximeters can be used with either disposable or reusable probes. 
• To optimize valid screening, use the specific probe recommended by the oximeter 
manufacturer. 
• A new guidance document is currently being developed by the FDA regarding the safe and 
effective use of pulse oximeters. When finalized, oximeters used for CCHD screening will need 
to meet the FDA standards. 
• Screening should be performed by qualified personnel, nurses and allied health technicians who 




• Newborns should be screened at 24-48 hours of age or shortly before discharge if <24 hours of 
age. 
• Earlier screening can lead to false-positive results as the newborn transitions from fetal to 
neonatal circulation. 
• Screening is recommended in the right hand (pre-ductal location) and 1 foot (post-ductal 
location). 
• Pulse oximetry measurement can be done in parallel or direct sequence: hand/foot at the same 
time using 2 oximeters OR hand first/then foot using 1 oximeter. 
• Measurement is complete once the waveform on the oximeter’s plethysmograph is stable or 
there is another indication that the device is appropriately tracking the infant’s pulse. 
• Pulse-oximetry monitoring should not replace a complete history and physical examination, 
which can sometimes detect CCHD before hypoxia develops.  
 
Interpreting the Results (Figure 1) 
• Negative screen: Any screening that is >95% in either extremity with <3% absolute 
difference in oxygen saturation between the upper and lower extremity  
 * Negative screen indicates a “pass” result, no diagnostic follow-up needed 
• Positive screen:  
1) Any oxygen saturation measure <90% 
2) Oxygen saturation is <95% in both extremities on 3 measures, each separated by  
 1 hour 
3)   There is a >3% absolute difference in oxygen saturation between the right hand and 
 the foot on 3 measures, each separated by 1 hour 
* Positive screen requires diagnostic follow-up 
* The criteria for a positive screen result may need to be modified in areas of high elevation. 
 
Diagnostic Follow-up 
• Follow-up for a positive screen result should be managed by the hospital or birthing center 
before discharge.  
• Any newborn with a positive screen result first requires a comprehensive evaluation for 
causes of hypoxemia. 
• In the absence of other findings to explain hypoxemia, CCHD should be excluded on the 
basis of a diagnostic echocardiogram. 
• Diagnostic echocardiograms should be interpreted by a pediatric cardiologist, and if possible 
the cardiologist should be consulted before obtaining the echocardiogram. 
• Telemedicine can be utilized for remote evaluation of the echocardiogram. 
• “If an echocardiogram cannot be performed in the hospital or birthing center and diagnosis 
by telemedicine is not possible, strong consideration should be made for transfer to another 
medical center for diagnosis.” 6 
• Protocols for arranging diagnostic follow-up should be established before implementing a 
CCHD screening protocol. 
 
Estimated Costs of Screening and Follow-up 
• Costs of a CCHD screening program are related to the following: staff time for screening, 
tracking results, and communicating with parents; purchase and maintenance of screening 
equipment; consumables associated with screening (eg, probes, adhesive wraps, cleaning 
supplies); costs associated with verifying a positive screen; and costs associated with 
treatment. 
• Cost estimates for pulse oximetry screening and follow-up have been reported at $5 or less 
per infant3,4 and up to $10 per infant, depending on the protocol.8 
• The screening process takes about 5 minutes of staff time, including communication with 
parents. 8 
• The cost of an echocardiogram is usually reimbursed well. 
• The cost of transport is high, and insurance reimbursement is variable.  
• Currently, there is no clear way for hospitals to bill for pulse-oximetry screening for CCHD 
as the CPT codes have not been defined.  
 
RECOMMENDATIONS FOR PARENT/FAMILY EDUCATION 
It is important for families to understand the rationale for screening and the limitations of pulse-
oximetry monitoring to detect CCHD.  A negative screen does not exclude the possibility of 
congenital heart disease. A simple fact sheet that explains the screening process and the steps for 
follow-up testing if the screen is positive can be very helpful for families. A multidisciplinary group 
at the University of Iowa Children’s Hospital has developed a fact sheet for parents (Figure 2). 9 
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Figure 1. The proposed pulse-oximetry monitoring protocol based on results from the right hand (RH) and either foot (F).6   
 
Screening for Critical Congenital Heart Disease (CCHD) 
 
What is congenital heart disease (CHD)? 
• CHD is a problem in the structure of the heart or its major blood vessels. It is the most common birth 
defect. 
• Some forms of CHD are very serious (critical). These can cause a baby to become sick soon after 
birth. 
 
How do you check for CHD? 
• Before your baby goes home, we will check for:  
o A sound in the baby’s heart (called a heart murmur)  
o Abnormal heart rate, breathing or blood pressure. 
• We will also do a pulse oximetry [ox-EH-mah-tree] test to check for low oxygen levels. 
 
What is pulse oximetry? 
• Pulse oximetry is a simple, painless test that measures how much oxygen is in the blood. It is 
sometimes called a “pulse ox.” 
• We will place a sticky strip, like a Band-Aid, on your baby’s hand and foot. A small red light on the 
strip measures your baby’s oxygen level.  
• This will only be on your baby’s skin for a few minutes. It will not hurt your baby.  
 
Why should my baby have pulse oximetry? 
• Low oxygen can be a sign of serious CHD. If your baby has CHD, this test may tell us before your 
baby becomes sick. 
• Low oxygen may also occur if: 
o Your baby’s lungs and heart are adjusting after birth  
o Your baby has a lung problem.  
 
What is a normal pulse-ox result? 
• A normal reading is 95 to 100 percent, with a difference of less than 3 points between the hand 
and the foot results. 
• It is possible for a baby with serious CHD to have a normal reading. Your baby should have regular 
doctor visits.  
 
What happens if my baby has low oxygen? 
• If the pulse-ox reading is low, we may consult with another doctor, or we may order more tests. 
• The most common test is called an echocardiogram, or “echo.” This is an ultrasound of the heart. The 
echo test looks at the heart and blood flow. It will not hurt your baby. 
 
When will we get the results and what if I have questions? 
The results will be reviewed with you before your baby leaves the hospital.  
If you have questions about CHD or pulse oximetry, talk to the doctor or nurse caring for your baby. 
 
Figure 2. University of Iowa Children’s Hospital, Parent Fact Sheet: Screening for Critical Congenital Heart Disease (CCHD) 9 
